S023 Late-Breaking Research: Session 1
DESCRIPTION
The Late Breaking Abstract Sessions showcase the most timely, high-impact, and unpublished research across the full spectrum of dermatology. Through a rigorous peer-review process, top-scoring submissions are selected for concise oral presentations that emphasize novelty and clinical relevance. This session features practice-changing clinical trials, population-based investigations, transformative technologies, translational biomarker studies, and innovative basic science. Abstracts addressing skin, hair, and nail disorders will be highlighted, with particular emphasis on discoveries that deepen understanding of disease mechanisms, inform therapeutic development, or improve the prevention and management of adverse events.
LEARNING OBJECTIVES
Evaluate late-breaking clinical, translational, and basic science studies for scientific rigor, novelty, and relevance to advancing dermatologic disease mechanisms and therapy.
Apply emerging evidence from trials, population studies, and biomarkers to improve clinical decision-making, patient outcomes, and prevention of adverse events.
Identify how novel discoveries and technologies impact dermatologic practice and healthcare systems, including implications for prevention, risk stratification, and multidisciplinary care.
SCHEDULE
9:00 AM
Combined Oral: Efficacy and Safety of Monotherapy Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the Pivotal COAST 1 and COAST 2 Phase 3 Trials and Efficacy and Safety of Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Combination With Topical Therapy in Participants With Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the SHORE Phase 3 Trial
Eric Lawrence Simpson, MD, FAAD
9:12 AM
Long-term efficacy and safety of MG-K10 for moderate-to-severe atopic dermatitis: 52-week results from a pivotal phase 3 trial
Jianzhong Zhang, MD
9:24 AM
Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results
Mahta Mortezavi
9:36 AM
Efficacy and Safety of Abrocitinib in Patients with Chronic Hand Eczema: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial
Robert Bissonnette, MSc, MD, FAAD
9:48 AM
Rademikibart monotherapy in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD): A 1-year, phase III, randomized, double-blinded, placebo-controlled trial (RADIANT-AD)
Cheng Zhou, MD
10:00 AM
Zumilokibart (APG777) Provides Early and Sustained Improvements in the Signs and Symptoms of Atopic Dermatitis: Results from the Phase 2 APEX Part A Study
Emma Guttman, MD, PhD, FAAD
10:12 AM
INTEGUMENT-INFANT: Once-Daily Roflumilast Cream 0.05% in Infants Aged 3–<24 Months With Atopic Dermatitis
Lawrence F. Eichenfield, MD, FAAD
10:24 AM
Pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis
Linda F. Stein Gold, MD, FAAD
10:36 AM
Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin: Phase 2b Efficacy and Safety Results Following 36-Weeks of Therapy in Severe-to-Very-Severe Alopecia Areata
David Rosmarin, MD, FAAD
10:48 AM
Molecular signatures of healthy skin aging highlight potential interventional anti-aging targets using tape strips
Helen Y. He, MD, FAAD
11:00 AM
Efficacy and Safety of Dersimelagon in Adults and Adolescents with Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Top-line Results from the INSPIRE Phase 3 Randomized Clinical trial
Amy (Dickey) Yeung
11:12 AM
Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies
Andrew Blauvelt, MD, FAAD
11:24 AM
Systemic ABCB5+ mesenchymal stem cell therapy targets the cutaneous and systemic disease burden of recessive dystrophic epidermolysis bullosa
Kiril Dimitrov
11:36 AM
Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo: Results of Two Phase 3 Studies (Viti-Up)
Thierry Passeron, MD, PhD
11:48 AM
Efficacy and safety of timolol maleate 0.5% gel for the treatment of proliferative superficial infantile hemangioma: A multicenter, randomized, double-blind, controlled, phase 3 trial
yi tian
DIRECTOR
Hensin Tsao, MD, PhD, FAAD
MODERATORS
April W. Armstrong, MD, MPH, FAAD
University of California Los Angeles
Aaron Mark Drucker, MD, FAAD
Joel M. Gelfand, MD, MSCE, FAAD
Kenneth B. Gordon, MD, FAAD
Sewon Kang, MD, FAAD
Paul Nghiem, MD, PhD, FAAD
Amy S. Paller, MD, FAAD
Sandy Sharon Tsao, MD, FAAD
SPEAKERS
Robert Bissonnette, MSc, MD, FAAD
Andrew Blauvelt, MD, FAAD
Kiril Dimitrov
RHEACELL Clinical Consultant
Lawrence F. Eichenfield, MD, FAAD
Emma Guttman, MD, PhD, FAAD
Helen Y. He, MD, FAAD
Mahta Mortezavi
Kymera Therapeutics, Inc.
Thierry Passeron, MD, PhD
David Rosmarin, MD, FAAD
Eric Lawrence Simpson, MD, FAAD
Linda F. Stein Gold, MD, FAAD
yi tian
Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China
Amy (Dickey) Yeung
Massachusetts General Hospital and Harvard Medical School
Jianzhong Zhang, MD
Peking University People`s Hospital
Cheng Zhou, MD
Peking University People's Hospital
DISCLOSURES
April W. Armstrong, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Amgen – Advisory Board(Honoraria); Arcutis Biotherapeutics – Consultant(Honoraria); Boehringer Ingelheim – Data Safety Monitoring Board(Honoraria); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Consultant(Honoraria); Dermsquared – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria); Galderma USA – Advisory Board(Honoraria); Incyte – Consultant (1099 relationship)(Honoraria); Janssen Biotech – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Ortho Dermatologics – Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi Genzyme – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); UCB – Advisory Board(Honoraria);
Robert Bissonnette, MSc, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Aclaris Therapeutics Inc. – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Aldena Therapeutics – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Almirall – Consultant (1099 relationship)(Honoraria), Other(Grants/Research Funding); Alumis – Investigator(Grants/Research Funding); Amgen – Consultant(Honoraria), Investigator(Grants/Research Funding); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria), Other(Grants/Research Funding); Arcutis, Inc. – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Arena Pharmaceuticals – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Areteia Therapeutics – Other(Grants/Research Funding); Artax Biopharma – Other(Grants/Research Funding); Attovia Therapeutics – Investigator(Grants/Research Funding), Other(Grants/Research Funding); BioMimetix JV, LLC – Other(Grants/Research Funding); Bluefin Biomedicine – Other(Grants/Research Funding); BMS – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Brickell Biotech, Inc – Other(Grants/Research Funding); Cara Therapeutics – Other(Grants/Research Funding); Eli Lilly and Company – Advisory Board(Honoraria), Investigator(Grants/Research Funding); GSK – Consultant (1099 relationship)(Honoraria), Other(Grants/Research Funding); Horizon Therapeutics Ireland DAC – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Indero – Stockholder Private Company(Stock); Inmagene Biopharmaceuticals – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Janssen Scientific Affairs, LLC – Consultant(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Nektar Therapeutics – Other(Grants/Research Funding); opsidio – Investigator(Grants/Research Funding); Opsidio – Other(Grants/Research Funding); Organon – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding), Other(Grants/Research Funding); Pelage Pharmaceuticals – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Pfizer Inc. – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Q32 Bio Inc. – Other(Grants/Research Funding); Sanofi – Other(Grants/Research Funding); Sanofi Aventis – Consultant(Honoraria); Sanofi Genzyme – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Sitryx – Consultant (1099 relationship)(Honoraria); Sun Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); T-Rex BioPharma – Consultant (1099 relationship)(Honoraria); Takeda Development Center Americas, Inc. – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); TARGET Pharma – Consultant(Honoraria), Investigator(Grants/Research Funding); Triveni Bio – Other(Grants/Research Funding); UCB – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); VYNE Therapeutics – Other(Grants/Research Funding); Xencor – Investigator(Grants/Research Funding), Other(Grants/Research Funding); Zai Lab – Investigator(Grants/Research Funding); Zura Bio – Other(Grants/Research Funding);
Andrew Blauvelt, MD, FAAD
AbbVie – Consultant(Honoraria); Almirall – Consultant(Honoraria), Speaker(Honoraria); Alumis – Consultant (1099 relationship)(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria); AnaptysBio – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Arcutis, Inc. – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Consultant(Honoraria), Speaker(Honoraria); Incyte Corporation – Consultant(Honoraria); Janssen-Ortho Inc. – Consultant(Honoraria); Leo Pharma – Speaker(Honoraria); Leo Pharma Inc – Consultant(Honoraria); Lipidio Pharmaceuticals – Stockholder Private Company(Stock); Novartis Pharmaceuticals Corp. – Consultant(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria), Stockholder Public Company(Stock); Pfizer Inc. – Consultant(Honoraria); Regeneron – Consultant(Honoraria); Sanofi – Consultant(Honoraria), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); UCB – Consultant(Honoraria), Speaker(Honoraria);
Kiril Dimitrov
RHEACELL – Consultant (1099 relationship)(Fees);
Aaron Mark Drucker, MD, FAAD
No financial relationships exist with ineligible companies.
Lawrence F. Eichenfield, MD, FAAD
AbbVie – Consultant(Honoraria); Abbvie – Investigator(Grants/Research Funding); Abeona Therapeutics – Consultant (1099 relationship)(Honoraria); Acrotech Biopharma Inc – Consultant (1099 relationship)(Honoraria); Almirall – Consultant(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Amryt Pharma – Consultant(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Investigator(Grants/Research Funding); Arcutis, Inc. – Consultant (1099 relationship)(Honoraria); Attovia Therapeutics – Consultant (1099 relationship)(Fees); Bristol-Myers Squibb – Consultant(Honoraria); Castle Biosciences – Consultant (1099 relationship)(Honoraria); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Chiesi Farmaceutici – Consultant (1099 relationship)(Honoraria); Dermata Therapeutics – Consultant (1099 relationship)(Stock); Dermavant Sciences, Inc. – Consultant(Honoraria); Eli Lilly – Consultant(Honoraria), Investigator(Grants/Research Funding); Elsevier Inc. – Other(Patent royalties or other compensation for Intellectual Property Rights); Forte Biosciences – Board of Directors(Fees), Board of Directors(Stock Options); Galderma Laboratories, L.P. – Consultant(Honoraria), Investigator(Fees); Incyte Corporation – Consultant(Honoraria); Janssen Pharmaceuticals, Inc – Consultant (1099 relationship)(Honoraria); Kenvue – Consultant (1099 relationship)(Honoraria); Krystal Biotech, Inc – Consultant(Honoraria); Kymera Therapeutics – Consultant (1099 relationship)(Honoraria); LEO Pharma, US – Consultant(Honoraria), Investigator(Fees); Lilly ICOS LLC – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Honoraria); Organon – Consultant (1099 relationship)(Honoraria); Ortho Dermatologics – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Sanofi/Regeneron – Consultant(Honoraria), Investigator(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Target RWE – Investigator(Grants/Research Funding); TopMD – Consultant(Stock Options); TRex Bio – Consultant (1099 relationship)(Honoraria); TrialSpark, Inc. – Consultant(Honoraria); UCB – Consultant(Honoraria); Verrica Pharmaceuticals Inc – Board of Directors(Fees), Board of Directors(Stock Options); Wiley-Blackwell – Other(Honoraria);
Joel M. Gelfand, MD, MSCE, FAAD
AbbVie – Consultant(Fees); Alumis – Consultant (1099 relationship)(Fees); Alyson Oliver Partner & Attorney – Consultant (1099 relationship)(Fees); Arcutis Biotherapeutics – Consultant (1099 relationship)(Fees); Arnold & Porter – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol Myers Squibb – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); FIDE – Consultant(Fees); Healio – Other(Fees); Inmagene Biopharmaceuticals – Data Safety Monitoring Board(Fees); International Psoriasis Council – Board of Directors(No Compensation Received); Johnson & Johnson Innovative Medicine – Consultant (1099 relationship)(Fees); Leo Pharma Inc – Consultant(Fees); Maui Derm – Speaker/Faculty Education(Fees); Medical Dermatology Society – Board of Directors(No Compensation Received); Moonlake – Data Safety Monitoring Board(Fees); National Psoriasis Foundation – Investigator(Grants/Research Funding); Neuroderm LTD – Other(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees);
Kenneth B. Gordon, MD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Grants/Research Funding); Almirall – Consultant(Honoraria); Amgen – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Incyte Corporation – Consultant(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Leo Pharma Inc – Consultant(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Novartis Pharmaceuticals Corp. – Advisory Board(Honoraria); Othro Dermatologics – Consultant(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Protagonist Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi Genzyme – Consultant(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); UCB – Consultant(Honoraria);
Emma Guttman, MD, PhD, FAAD
AbbVie – Consultant(Fees), Consultant(Honoraria); Almirall – Consultant(Fees); Amgen – Consultant(Fees), Investigator(Grants/Research Funding); AnaptysBio – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Apogee Therapeutics – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Apollo Therapeutics Ltd – Investigator(Grants/Research Funding); Artax Biopharma – Consultant (1099 relationship)(Fees); Astria Therapeutics – Consultant (1099 relationship)(Fees); Bambusa Therapeutics Inc – Consultant (1099 relationship)(Fees); Biolojic Design – Consultant (1099 relationship)(Fees); Bionyra Pharma – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant(Fees); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Celldex – Consultant (1099 relationship)(Fees); Cue Biopharma – Consultant (1099 relationship)(Fees); CytoReason – Consultant (1099 relationship)(Fees); DBV Technologies – Consultant (1099 relationship)(Fees); Dualitas Therapeutics – Consultant (1099 relationship)(Fees); Electra Therapeutics – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Enveda Biosciences – Consultant (1099 relationship)(Fees); Evommune, Inc. – Consultant (1099 relationship)(Fees); Galderma Research & Development, LLC – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Generate Biomedicines – Consultant (1099 relationship)(Fees); Gilead Sciences, Inc – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Infimmune – Consultant (1099 relationship)(Fees); Inmagene Biopharmaceuticals – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Janssen – Consultant (1099 relationship)(Fees); Jasper Therapeutics – Consultant (1099 relationship)(Fees); Kymera Therapeutics – Consultant (1099 relationship)(Fees); Kyowa Hakko Kirin Pharma, Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Leo Pharma Inc – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); Matchpoint Therapeutics – Consultant (1099 relationship)(Fees); Merck – Consultant(Fees), Consultant(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Nektar Therapeutics – Consultant (1099 relationship)(Fees); Opsidio – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); Propeller Bio – Consultant (1099 relationship)(Fees); Proteologix US Inc – Consultant (1099 relationship)(Fees); RAPT Therapeutics – Consultant (1099 relationship)(Fees), Consultant (1099 relationship)(Honoraria), Consultant (1099 relationship)(Stock Options), Investigator(Grants/Research Funding); RayThera – Consultant (1099 relationship)(Fees); Regeneron – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); Rubedo Life Sciences – Consultant (1099 relationship)(Fees); Sanofi – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding); SATO Pharmaceutical Co., Ltd – Consultant(Fees); Sitryx – Consultant (1099 relationship)(Fees); Sun Pharma Advanced Research Company (SPARC) – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); Teva – Consultant (1099 relationship)(Fees); TRex Bio – Consultant (1099 relationship)(Fees); Triveni Bio – Consultant (1099 relationship)(Fees); UCB – Consultant(Fees), Investigator(Grants/Research Funding); Ventyx Biosciences – Consultant (1099 relationship)(Fees); VeraDermics Inc. – Consultant (1099 relationship)(Fees); VRG Therapeutics – Consultant (1099 relationship)(Fees); Xencor – Consultant (1099 relationship)(Fees);
Helen Y. He, MD, FAAD
CeraVe – Advisory Board(Honoraria); SkinBetter Science – Advisory Board(Honoraria);
Sewon Kang, MD, FAAD
Allergan, Inc – Advisory Board(Honoraria); CeraVe/Valeante – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria); Estee Lauder – Advisory Board(Honoraria); Galderma USA – Advisory Board(Honoraria); Incyte Corporation – Data Safety Monitoring Board(Fees); Rapalogix Health – Advisory Board(Stock Options); Walgreens Boots Alliance, Inc. – Investigator(Grants/Research Funding);
Mahta Mortezavi
No financial relationships exist with ineligible companies.
Paul Nghiem, MD, PhD, FAAD
Almirall – Consultant(Honoraria); Bristol-Myers Squibb – Investigator(Grants/Research Funding); EMD Serono – Consultant(Fees); Merck & Co., Inc – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria);
Amy S. Paller, MD, FAAD
AbbVie – Data Safety Monitoring Board(Honoraria), Investigator(Grants/Research Funding); Abeona Therapeutics – Data Safety Monitoring Board(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); BioCryst Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria), Data Safety Monitoring Board(Honoraria); BioMendics, LLC – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria); Castle Creek Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Chiesi Farmaceutici – Consultant (1099 relationship)(Honoraria); Daiichi Sankyo – Data Safety Monitoring Board(Honoraria); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Eli Lilly – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Galderma – Data Safety Monitoring Board(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Johnson & Johnson Innovative Medicine – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Krystal Biotech, Inc – Consultant(Honoraria); L'Oréal France – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Pelthos Therapeutics – Consultant (1099 relationship)(Honoraria); Quoin Pharmaceuticals Ltd – Consultant (1099 relationship)(Honoraria); Regeneron – Consultant(Honoraria), Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);
Thierry Passeron, MD, PhD
AbbVie – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Almirall – Advisory Board(Honoraria); Amgen – Consultant(Honoraria); Astellas Pharma US, Inc – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Speaker(Honoraria); Bioderma – Speaker/Faculty Education(Honoraria); Celgene Corporation – Investigator(Grants/Research Funding); Cutera, Inc. – Advisory Board(Honoraria); Galderma Research & Development, LLC – Advisory Board(Honoraria); GlaxoSmithKline – Speaker/Faculty Education(Honoraria); Hyphens Pharma – Speaker/Faculty Education(Honoraria); Incyte Corporation – Investigator(Fees), Speaker/Faculty Education(Honoraria); ISDIN – Advisory Board(Honoraria), Speaker(Honoraria); Janssen-Cilag – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Journal of the European Academy of Dermatology and Venereology – Other(No Compensation Received); L'Oréal Research and Innovation – Speaker/Faculty Education(Honoraria); La Roche-Posay Laboratorie Pharmaceutique – Speaker/Faculty Education(Honoraria); Leo Pharma Inc. – Speaker/Faculty Education(Honoraria); Lilly ICOS LLC – Speaker/Faculty Education(Honoraria); Mesoestetic USA Laboratories – Advisory Board(Honoraria); MSD – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Speaker/Faculty Education(Honoraria); Symrise – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); Vichy Laboratoires – Advisory Board(Honoraria), Speaker(Honoraria); VYNE Therapeutics – Advisory Board(Honoraria);
David Rosmarin, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Abcuro, Inc. – Consultant(Honoraria); Almirall – Consultant (1099 relationship)(Honoraria); AltruBio Inc. – Consultant(Honoraria); Amgen – Speaker(Honoraria); Arena Pharmaceuticals – Consultant(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Celgene – Investigator(Grants/Research Funding); Celgene Corporation – Advisory Board(Honoraria), Speaker(Honoraria); Concert Pharmaceuticals – Consultant(Honoraria), Data Safety Monitoring Board(Honoraria); CSL Behring – Consultant(Honoraria); Dermavant Sciences – Advisory Board(Honoraria), Speaker(Honoraria); Dermira – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding), Other(Other Financial Benefit), Speaker(Honoraria); Janssen Biotech – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Kyowa Hakko Kirin Pharma, Inc. – Consultant(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Merck & Co., Inc – Investigator(Grants/Research Funding); Nektar Therapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); RAPT Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Recludix Pharma – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Revolo Therapeutics – Consultant(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant(Honoraria); UCB – Advisory Board(Honoraria); Viela Bio – Advisory Board(Honoraria); Zura Bio – Consultant (1099 relationship)(Honoraria);
Eric Lawrence Simpson, MD, FAAD
AbbVie – Consultant(Fees), Investigator(Grants/Research Funding); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Acrotech Biopharma Inc – Investigator(Grants/Research Funding); Amgen – Consultant(Fees), Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Consultant(Fees); Arcutis, Inc. – Investigator(Grants/Research Funding); ASLAN – Investigator(Grants/Research Funding); Astria Therapeutics – Consultant (1099 relationship)(Fees); Attovia Therapeutics, Inc – Consultant (1099 relationship)(Fees); Bambusa Therapeutics Inc – Consultant (1099 relationship)(Fees); Castle Biosciences – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); CorEvitas – Consultant(Fees), Investigator(Grants/Research Funding); Demira – Consultant(Fees); Dermavant – Investigator(Grants/Research Funding); Dermira – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant(Fees), Investigator(Grants/Research Funding); Evomunne – Consultant (1099 relationship)(Fees); FIDE – Speaker/Faculty Education(Fees); Genentech, Inc. – Consultant (1099 relationship)(Fees); Impetus Healthcare – Consultant (1099 relationship)(Fees); Incyte Corporation – Consultant(Fees), Investigator(Grants/Research Funding); Inmagene Biopharmaceuticals – Consultant (1099 relationship)(Fees); Innovaderm Research Inc. – Consultant (1099 relationship)(Fees); Janssen Pharmaceuticals, Inc – Consultant (1099 relationship)(Fees); Kymera Therapeutics – Consultant (1099 relationship)(Fees); La Fonderie Ressources – Consultant (1099 relationship)(Fees); Leo Pharma Inc. – Consultant(Fees); National Jewish Health – Investigator(Grants/Research Funding); NUMAB Therapeutics AG – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant(Fees), Investigator(Grants/Research Funding); Recludix Pharma – Consultant (1099 relationship)(Fees); Regeneron – Consultant(Fees), Investigator(Grants/Research Funding); Roche Products Ltd – Consultant (1099 relationship)(Fees); Sanofi – Investigator(Grants/Research Funding); Sanofi Genzyme – Consultant(Fees), Investigator(Grants/Research Funding); SITRYX – Consultant (1099 relationship)(Fees); Target RWE – Investigator(Grants/Research Funding); Veriskin – Investigator(Grants/Research Funding);
Linda F. Stein Gold, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Actavis – Speaker(Honoraria); Almirall – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Alumis – Investigator(Grants/Research Funding); AnaptysBio – Consultant(Grants/Research Funding), Investigator(Grants/Research Funding); BMS – Consultant(Honoraria), Speaker(Honoraria); Botanix Pharmaceuticals – Consultant(Honoraria); Cutera, Inc. – Consultant(Honoraria); Galderma Laboratories, L.P. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Honoraria), Consultant(Honoraria); Janssen Scientific Affairs, LLC – Consultant(Honoraria); Journey Medical Corporation – Investigator(Grants/Research Funding); Kymera Therapeutics – Advisory Board(Honoraria); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Honoraria); Leo Pharma Inc. – Investigator(Grants/Research Funding); LEO Pharma, US – Advisory Board(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding); Oruka Therapeutics – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker/Faculty Education(Honoraria); Promius Pharmaceuticals – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria), Speaker/Faculty Education(Honoraria); Sun Pharmaceutical Industries Ltd. – Speaker(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); Taro Pharm – Advisory Board(Honoraria), Consultant(Honoraria); UCB – Consultant(Honoraria); Valeant Pharmaceuticals International – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
yi tian
No financial relationships exist with ineligible companies.
Hensin Tsao, MD, PhD, FAAD
Epiphany Dermatology – Advisory Board(Honoraria), Advisory Board(Stock Options); Massachusetts General Hospital – Employee(Salary); UpToDate, Inc. – Other(Honoraria);
Sandy Sharon Tsao, MD, FAAD
Beiersdorf, Inc. – Consultant (1099 relationship)(Honoraria); Epiphany Dermatology – Advisory Board(Stock); WorldCare Clinical LLC – Consultant (1099 relationship)(Honoraria);
Amy (Dickey) Yeung
Disc Medicine – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Guidepoint Global, LLC – Consultant (1099 relationship)(Honoraria); Mitsubishi Tanabe Pharma Development America – Investigator(Grants/Research Funding), Speaker(Other Financial Benefit); Pierre Fabre – Consultant (1099 relationship)(Honoraria); Portal Therapeutics – Investigator(Grants/Research Funding), Other(Honoraria); Recordati rare diseases – Consultant (1099 relationship)(Honoraria);
Jianzhong Zhang, MD
No financial relationships exist with ineligible companies.
Cheng Zhou, MD
No financial relationships exist with ineligible companies.